Glaukos Provides COVID-19 Pandemic Update

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retina diseases, today provided an update on the actions it is taking in response to the COVID-19 pandemic. In order to prioritize the health and safety of employees, healthcare professionals, patients and its communities, while continuing to support its customers, Glaukos has acted qu

Full Story →